ORIC-259 is a potential first-in-class small molecule mRNA degrader targeting CIP2A, a previously undruggable target. Cancer ...
CN Bio, a leading Organ-on-a-chip (OOC) company de-risking drug discovery and development pipelines by enabling earlier, more ...
Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced an oral presentation will be featured at the upcoming ...
Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient ou ...
Dr. Meltzer joins Avilar as the company advances its lead ATAC program toward the clinic. The program is an ATAC designed to ...
The incidence of melanoma is steadily rising, with annual cases projected to increase by more than 50% between 2020 and 2040.
Motivista is a prescription digital therapeutic indicated for the treatment of negative symptoms of schizophrenia as an ...
WO 2026/178627 covers methods, uses and compositions pairing Streptococcus salivarius SALI-10 with sorbitol, creating a ...
Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral ...
FDA clearance of its Investigational New Drug (IND) application for MC001, the Company's first-in-class dimeric ...
Privo Technologies today announced results from the CLN-004 Phase 2 (Cohort 1) trial evaluating PRV111, a nanoengineered, ...
UPPSALA, SE / ACCESS Newswire / October 5, 2026 / Senzime (STO:SEZI)(OTCQX:SNZZF) - "We reaffirm our target of reaching ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results